{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-261753","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.527389+00:00","generated_at":"2026-05-17T00:55:43.521955+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lyell CEO Lynn Seely appointed interim CFO; Veronica Sanchez Bulis named principal accounting officer","bullets":["Board appointed CEO Lynn Seely as interim principal financial officer on Oct 31, 2025; also remains CEO and director.","Veronica Sanchez Bulis, VP Corporate Controller since Aug 2021, appointed principal accounting officer.","Bulis previously held senior finance roles at Sangamo Therapeutics and Core-Mark International; began career at EY and Deloitte.","No departure or replacement of a named executive officer was disclosed; changes effective immediately."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-261753","json":"https://secwatch.observer/filing/0001193125-25-261753.json","markdown":"https://secwatch.observer/filing/0001193125-25-261753.md","text":"https://secwatch.observer/filing/0001193125-25-261753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525261753/0001193125-25-261753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525261753/d73457d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:55:43.521955+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}